Investors in U.S. Physical Therapy, Inc. (USPH) need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 20, 2025 $105 Call  had some of the highest implied volatility of all equity options today. What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It ...

Company Performance - DaVita HealthCare reported quarterly earnings of $2 per share, exceeding the Zacks Consensus Estimate of $1.75 per share, but down from $2.38 per share a year ago, representing an earnings surprise of 14.29% [1] - The company posted revenues of $3.22 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.38% and up from $3.07 billion year-over-year [2] - Over the last four quarters, DaVita has surpassed consensus EPS estimates three times and topped revenue estimates four times [2] Stock Outlook - DaVita HealthCare shares have declined approximately 3.9% since the beginning of the year, compared to a 3.8% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $2.89 on revenues of $3.3 billion, and for the current fiscal year, it is $10.76 on revenues of $13.46 billion [7] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which DaVita belongs, is currently ranked in the top 18% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry outlook can significantly impact stock performance [5][8]

Core Viewpoint - U.S. Physical Therapy (USPH) reported quarterly earnings of $0.48 per share, exceeding the Zacks Consensus Estimate of $0.46 per share, but down from $0.51 per share a year ago, indicating a mixed performance in earnings [1] Financial Performance - The company achieved revenues of $183.79 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.60% and showing an increase from $155.68 million year-over-year [2] - Over the last four quarters, U.S. Physical Therapy has exceeded consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Performance - U.S. Physical Therapy shares have declined approximately 19.3% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.79 on revenues of $189.46 million, and for the current fiscal year, it is $2.63 on revenues of $752.89 million [7] - The estimate revisions trend for U.S. Physical Therapy is mixed, which may change following the recent earnings report [6] Industry Context - The Medical - Outpatient and Home Healthcare industry, to which U.S. Physical Therapy belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

DaVita Inc. (DVA) is scheduled to report first-quarter 2025 results on May 12, after the closing bell.In the last reported quarter, the company’s earnings per share (EPS) of $2.24 beat the Zacks Consensus Estimate by 1.4%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on three occasions and missed once, delivering an earnings surprise of 5.4%, on average. (See the Zacks Earnings Calendar to stay ahead of market-making news.)Let’s check out the factors that have shap ...

Core Viewpoint - U.S. Physical Therapy (USPH) reported quarterly earnings of $0.41 per share, missing the Zacks Consensus Estimate of $0.46 per share, and showing a decline from $0.51 per share a year ago, indicating a -10.87% earnings surprise [1] Financial Performance - The company posted revenues of $183.79 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.60%, compared to $155.68 million in the same quarter last year [2] - Over the last four quarters, U.S. Physical Therapy has exceeded consensus revenue estimates four times [2] Stock Performance - U.S. Physical Therapy shares have declined approximately 19.3% since the beginning of the year, while the S&P 500 has decreased by -4.7% [3] - The current Zacks Rank for the stock is 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.79 on revenues of $189.46 million, and for the current fiscal year, it is $2.63 on revenues of $752.89 million [7] - The estimate revisions trend for U.S. Physical Therapy is mixed, which may change following the recent earnings report [6] Industry Context - The Medical - Outpatient and Home Healthcare industry is currently in the top 22% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

The latest trading session saw DaVita HealthCare (DVA) ending at $143.96, denoting a +0.94% adjustment from its last day's close. The stock's performance was ahead of the S&P 500's daily gain of 0.44%. At the same time, the Dow added 0.7%, and the tech-heavy Nasdaq gained 0.27%. The the stock of kidney dialysis provider has fallen by 0.9% in the past month, lagging the Medical sector's gain of 1.16% and the S&P 500's gain of 10.62%. The upcoming earnings release of DaVita HealthCare will be of great interes ...

Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 19.35%. A quarter ago, it was expected that this company would post earnings of $0.15 per share when it actually produced earnings of $0.14, delivering a surprise of -6.67%.Over the last four quar ...

Core Viewpoint - The Pennant Group, Inc. reported quarterly earnings of $0.27 per share, exceeding the Zacks Consensus Estimate of $0.22 per share, and showing an increase from $0.20 per share a year ago, indicating a positive earnings surprise of 22.73% [1] Financial Performance - The company achieved revenues of $209.84 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3.68%, and up from $156.92 million year-over-year [2] - Over the last four quarters, The Pennant Group has exceeded consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - The Pennant Group shares have increased by approximately 0.8% since the beginning of the year, contrasting with the S&P 500's decline of -3.9% [3] - The current consensus EPS estimate for the upcoming quarter is $0.26 on revenues of $206.89 million, and for the current fiscal year, it is $1.08 on revenues of $832.9 million [7] Industry Outlook - The Medical - Outpatient and Home Healthcare industry, to which The Pennant Group belongs, is currently ranked in the top 18% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]

Company Overview - Encompass Health (EHC) currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook for investors [3] Price Performance - EHC shares have increased by 2.88% over the past week, outperforming the Zacks Medical - Outpatient and Home Healthcare industry, which rose by 2.41% [5] - Over the past month, EHC's price change is 19.07%, significantly higher than the industry's 2.41% [5] - In the last quarter, EHC shares have risen by 16.8%, and over the past year, they have gained 40.17%, while the S&P 500 has moved -5.55% and 13.72%, respectively [6] Trading Volume - EHC's average 20-day trading volume is 1,151,747 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the past two months, 7 earnings estimates for EHC have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from $4.80 to $4.96 [9] - For the next fiscal year, 7 estimates have also moved upwards without any downward revisions [9] Conclusion - Given the strong price performance, positive earnings outlook, and high momentum score, EHC is positioned as a solid investment opportunity [11]

Company Overview - Astrana Health, Inc. (ASTH) is expected to report a year-over-year decline in earnings of 25.8%, with an estimated EPS of $0.23 for the quarter ended March 2025 [3][12] - Revenue is projected to be $635.17 million, reflecting a significant increase of 57.1% compared to the same quarter last year [3] Earnings Expectations - The earnings report is scheduled for release on May 8, 2025, and could lead to stock price movements depending on whether the results exceed or fall short of expectations [2] - The consensus EPS estimate has been revised 6.67% higher in the last 30 days, indicating a more optimistic outlook from analysts [4][10] Earnings Surprise Prediction - The Zacks Earnings ESP for Astrana Health is +13.04%, suggesting a higher likelihood of beating the consensus EPS estimate [11] - The company currently holds a Zacks Rank of 3 (Hold), which indicates a moderate outlook [11] Historical Performance - In the last reported quarter, Astrana Health was expected to post earnings of $0.09 per share but instead reported a loss of $0.15, resulting in a surprise of -266.67% [12] - Over the past four quarters, the company has only beaten consensus EPS estimates once [13] Industry Context - In the Zacks Medical - Outpatient and Home Healthcare industry, Elanco Animal Health Incorporated (ELAN) is also expected to report earnings, with an EPS estimate of $0.31, reflecting a year-over-year decline of 8.8% [17] - Elanco's revenue is anticipated to be $1.17 billion, down 3.1% from the previous year [17]